To learn more about important health issues for FSHD patients, click on the drawers below:
FSHD patients ask their doctors to prescribe physical therapy when they feel their FSHD is progressing more rapidly than usual; periodically to monitor how they perform their exercises; and to rehabilitate specific conditions or injuries such as strained or pulled muscles or injuries from falls. Many find it useful to go to a PT for a “tune-up” from time to time.
Many people with FSHD enjoy swimming and find it beneficial. Swimming has a low impact on the joints and bones and a low risk of injury. The buoyancy of the water provides resistance, which affords the opportunity for gentle exercise and also enables some people to do things they are unable to do on land—for example, someone who can’t stand or walk on land may be able to stand and walk in water. It can also be beneficial to do stretching exercises in the water.
Watsu®, a form of massage done in the water, combines the benefits of ordinary massage and being in the water. Both massage and Watsu should be done only by certified professionals. For FSHD patients with reduced mobility, being in the water can provide freedom of movement and a welcome feeling of exhilaration, energy, and relaxation. In recent years there have been an increased number of therapeutic swimming pools with access and special programs for disabled people; some of these pools have extremely warm water, which can be soothing for people who can’t move quickly or who are in pain.
For some people with FSHD who can no longer walk, standing with the aid of a standing frame can be beneficial. A standing frame is a piece of equipment that can straighten and elevate people into a standing position and support them in that position. For some people, standing in a standing frame can help maintain range of motion and reduce the possibility of contractures, relieve pressure on the posterior, increase circulation, reduce stress, realign the internal organs, and provide weight bearing to preserve bones.
As with all exercise, it’s important for FSHD patients to consult with their doctors and physical therapists before beginning a swimming program and before using a standing frame. The risk of overuse is ever present, so it’s essential to monitor closely how you feel. When in doubt about an exercise, seek professional help. When in pain, stop doing it. See also Physical Therapists.
Download our Physical Therapy and FSHD brochure, written by Wendy M. King, PT, and Shree Pandya, PT, MS, and published by the FSH Society. Links to Recent Publications on FSHD and Physical Therapy and Exercise
- 2010 FSH Society International Patient and Researcher Network Meeting, July 30—August 1, 2010. Presentation slides for talk titled: Physical Activity and Exercise: A Physician’s and a Patient’s Perspectives, by Craig M. McDonald, MD, PhD, RRTC/NMD Director Rehabilitation Research and Training Center in Neuromuscular Diseases, University of California, Davis, and Nils Hakansson, Patient. Click here to read Abstract
- Pandya S, King WM, Tawil R. Facioscapulohumeral dystrophy. Phys Ther. 2008 Jan;88(1):105-13. Epub 2007 Nov 6. Click here to read Abstract.
- van der Kooi EL, Kalkman JS, Lindeman E, Hendriks JC, van Engelen BG, Bleijenberg G, Padberg GW. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. J Neurol. 2007 Jul;254(7):931-40. Epub 2007 Mar 14. Click here to read Abstract.
Occupational Therapy and Assistive Technology
- For more information about occupational therapy, visit the website of the American Occupational Therapy Association.
- The National Registry of Rehabilitation Technology Suppliers (NRRTS) is a professional organization of wheelchair dealers that provides training and credentialing.
- Many of the most knowledgeable and experienced wheelchair dealers are credentialed by and registered with NRRTS.
- Several organizations sponsor disability products trade shows. The largest is the Abilities Expo, which is held in several cities each year.
- Easter Seals offers useful information about accessibility, equipment, and home modifications.
- To learn more about Dragon NaturallySpeaking voice recognition software, visit Nuance Communications.
* * * * * * * * *
Chronic Pain in Persons With Facioscapulohumeral Dystrophy and Other Neuromuscular Disorders, by R. Ted Abresch, Department of Physical Medicine and Rehabilitation, UC Davis Davis California 95616 USA Introduction Recent preliminary research suggests that pain may be a significant problem for many persons with FSHD. For example, Bushby et al. recently reported on four individuals with FSHD who identified pain as their most disabling symptom and complained of between three to seven separate pain complaints. In addition, our group found that 83 percent of a sample of 811 individuals with various neuromuscular diseases (NMDs), including 64 persons with FSHD, reported at least some ongoing pain problems. Moreover, the frequency and severity of pain in their combined sample of patients with FSHD, MMD, and a sample of patients with limb-girdle syndrome was significantly greater than levels of pain reported by the general US population. In a more recent study, our group surveyed 193 individuals with a variety of NMDs, including 18 patients with FSHD and 26 patients with MMD, and found that 73 percent of the sample as a whole (89 percent of patients with FSHD and 69 percent of those with MMD) reported pain problems, with 27 percent of the overall sample reporting severe pain (19 percent of patients with FSHD and 50 percent of patients with MMD). We found that pain was reported to interfere moderately with a number of activities of daily living across all of the NMD diagnostic groups (range of interference ratings, 2.6 to 4.63 on 0-10 interference ratings scales) and to occur all over the body (least common, abdomen/pelvis at 16 percent; most common, back at 49 percent). However, we were unable to examine pain interference, pain sites, and pain treatments as a function of the diagnostic group due to the low sample sizes of the individual NMD diagnostic groups in our previous study. Although the preliminary findings from our group and others indicate that chronic pain can be a serious problem for many persons with FSHD, much remains unknown about the nature and scope of pain in these patient populations. Importantly, most of the research on pain that has been performed with patients with FSHD has reported findings from a mixed population of patients with limited sample sizes for particular diagnoses. This limits both the reliability and generalizability of the available findings. Descriptive analyses regarding pain with larger samples of patients with specific diagnoses would provide for greater reliability of the findings and would allow us to confirm (or question) previously published data concerning pain in patients with these conditions. Moreover, because FSHD is a progressive disease, it is possible that the onset of pain, and the severity of pain once it develops, is related to a patient’s age. This study sought to address the need for more information about the nature and scope of pain in persons with FSHD and myotonic muscular dystrophy.
Methods Retrospective, cross-sectional study performed using a community-based survey. Participants were recruited from the NIH-funded National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members (n = 296); the University of Washington NMD Clinic list (n = 87); the Quality of Life Pediatric Survey Study (n = 8); and four participants who independently contacted study personnel. A total of 296 potential subjects with MMD or FSHD contacted us. Of these, 235 (93 percent) completed and returned a mail survey questionnaire on the nature and scope of their pain. The survey included questions asking about demographic information, NMD-related information, pain intensity, pain interference, pain location, and pain treatments. All participants provided basic demographic information about their gender, age, race/ethnicity, educational level, marital and employment status. They also provided information about their NMD diagnosis, including approximate date of diagnosis, type of physician who made the diagnosis, whether or not they had received a DNA confirmation of diagnosis, and their use of assistive devices for ambulation. Average pain intensity over the past week was assessed using an 11-point numerical rating scale (0 = “no pain” to 10 = “pain as bad as could be”) taken from the Grading of Chronic Pain scale (GCP). Pain interference with daily activities was assessed using a 12-item interference scale adapted from the Brief Pain Inventory Pain Interference scale (BPI). Participants were asked to indicate whether or not they experience bothersome pain in one or more of 17 specific body sites (head, neck, shoulders, upper back, lower back, arms, elbows, wrists, hands, buttocks, hips, chest, abdomen/pelvis, legs, knees, ankles, and feet). Participants were asked to indicate if they were currently using or had ever used any of 25 specific pain treatments (physical therapy, nerve blocks, biofeedback/relaxation training, acupuncture, magnets, massage, hypnosis, counseling/psychotherapy, mexiletine, Neurontin®, tricyclic antidepressants, narcotics/opioids, acetaminophen, aspirin/ibuprofen, valium, Tegretol®, baclofen, TENS units, anticonvulsants, chiropractic adjustments, heat, ice, marijuana, strengthening exercises or range of motion exercises). Results/Discussion More individuals with FSHD (82 percent) than with MMD (60 percent) reported pain. The most frequency of pain sites for both diagnostic groups were lower back (66 percent MMD, 74 percent FSHD) and legs (60 percent MMD, 72 percent FSHD). Moreover, the average pain severity reported in patients with FSHD in our sample (4.40 out of 10 in the current sample) and percent of patients with FSHD who report severe pain (23 percent in the current sample) also replicate previous findings. These pain problems are chronic with a mean duration of pain being 11-13 years in our samples. This finding, when considered in light of both the high frequency of pain in general and the existence of subgroups of patients (about 25 percent in both samples) who report severe pain, underscores the need to identify and provide effective pain treatments for patients with these neuromuscular diseases. Both FSHD and MMD patients endorsed generally similar levels of interference of pain with functioning, although there was a slight trend for patients with MMD (range of interference ratings, 2.14 to 4.17/10) to report higher levels of interference with some activities than patients with FSHD (range, 1.14 to 3.65/10). Pain was reported to have a moderate degree (3.73 and 3.53/10) of interference with enjoyment of life. Moreover, the strength of the associations found between pain severity and interference with the life activities tended to be strong (correlation coefficients greater than .50 for six of the 12 activities; the correlation coefficient was never less than .30). Modern biopsychosocial pain rehabilitation treatments focus not only on the pain itself, but also on the extent to which pain interferes with function. The significant pain interference reported by the patients in this study, when considered in light of the multi-domain focus of contemporary pain treatments, raises the possibility that patients with neuromuscular disease and chronic pain might benefit from pain rehabilitation approaches. Overall, the sites of pain reported by these patients reflect the body areas that are commonly affected by these NMDs (e.g., low back and legs as most common; chest, buttocks, and head as relatively less common). The most frequent pain site for both diagnostic groups was the low back. This reflects the fact that low back pain is a common site of pain in the able-bodied adult population. In both FSHD and MMD the degree of back pain may be exacerbated by the fact that the trunk and neck flexors are among the weakest muscle groups in both of these disorders. Moreover, in both diseases there is a significant imbalance between the extensors and flexors of the neck and the trunk. As the individuals become weaker, the biomechanical stresses are increased and pain may become more pronounced. This is supported by the fact that subjects with FSHD reported a significantly older age at which pain began in their hands and ankles compared to the subjects with MMD. No single treatment for pain has been shown to be widely effective for subjects with FSHD and MMD. No treatment was currently used by more than 46 percent of all of the patients reporting pain, or by more than 42 percent of the patients reporting severe pain. The most common treatments were ibuprofen or aspirin (used by 46 percent of patients with pain), acetaminophen (used by 34 percent), and strengthening exercises (used by 29 percent). Of those treatments that had been tried, the most effective (rated as providing at least 5/10 relief) were ibuprofen/aspirin, opioids, massage, chiropractic manipulation, nerve blocks, heat, and marijuana. However, it should also be noted that many of these treatments also have significant drawbacks. For example, opioids, which were rated as the most effective (6.49/10) in this sample, had been tried by 25 percent of the sample, but were only currently being used by 8 percent of the sample. These data suggest that the pain relief gained from the opioids did not outweigh their side effects (grogginess and constipation) when taken at the doses required to provide substantial relief. Similarly, marijuana, although reported to be highly effective (6.00/10), was still used by only a little over half of the patients who had tried it (4 percent of the sample using, 7 percent had tried). The significant side effects (such as decreased motivation) and significant problems with access may decrease the desirability of this treatment. The other treatments that were rated as being relatively highly effective tend be short lasting. This may explain the fact that many of the patients who had ever tried massage, chiropractic manipulation, and nerve blocks no longer receive these treatments. The only treatment that was relatively highly effective and was still being used by a substantial number of patients (26 percent) was heat. Perhaps this is because heat is an extremely accessible treatment (most people own a hot water bottle or heating pad) that has few, if any, negative side effects. Overall, the findings suggest that there remain too few options for pain relief for patients with MMD and FSHD and chronic pain. There is a substantial need for the development of effective and long-lasting pain treatments for persons with MMD and FSHD that can be made easily available and that have few negative side effects. Pain is likely related, at least in part, to fatigue. Our results are consistent with a recent study of NMD patients that included 139 subjects with FSHD and 322 subjects with MMD. Severe fatigue was reported by 61-74 percent of these patients and the severity of the fatigue was correlated with an increase in the number of problems with physical functioning, mental health, and bodily pain. Although the causal relationship is not clear, it is likely that physical disability leads to both pain and fatigue conjointly, but chronic pain would certainly worsen fatigue symptoms.
Conclusion The findings from this study indicate that pain is a common problem in both FSHD and MMD, with the majority of adults with these conditions reporting pain. The most frequent pain sites for both diagnostic groups were lower back and legs. Significant differences between diagnostic groups in frequency of pain at specific sites were found in shoulders, hips, and feet, with participants with FSHD reporting pain more often in their shoulders and hips, and participants with MMD reporting pain more often in their feet and hands. These findings highlight the need to identify and provide effective pain treatments for patients with FSHD and MMD. Future work needs to address chronic pain in a variety of other neuromuscular diseases.
Scapular Fixation Surgery
- American Academy of Orthopaedic Surgeons
- American Shoulder and Elbow Surgeons
- The Pediatric Orthopaedic Society of North America
Links to Recent Articles About Scapulothoracic Fusion in FSHD
- 2010 FSH Society International Patient and Researcher Network Meeting, July 30–August 1, 2010. Presentation slides for talk titled: Scapular Fixation Surgery for People with FSHD, by Leigh Ann Curl, MD, Orthopedic Surgery, Sports Medicine, Knee and Shoulder, Harbor Hospital, Baltimore, Maryland. Click here to read Abstract.
- Diab M, Darras BT, Shapiro F. Scapulothoracic fusion for facioscapulohumeral muscular dystrophy. J Bone Joint Surg Am. 2005 Oct;87(10):2267-75. Click here to read Abstract.
- Mummery CJ, Copeland SA, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev. 2003;(3):CD003278. Click here to read Abstract.
Oxygen supplementation can be detrimental to FSHD patients with hypercarbic (high CO2) respiratory failure and lead to worsening CO2 levels. Oxygen should generally not be administered unless BiPAP or similar ventilatory support is also being used. Your physician and a pulmonologist can help you periodically monitor CO2 levels when in the office or pulmonary function lab in the hospital. Pulmonary and Respiratory Health and FSHD Fatigue is often part of FSHD because the muscles of FSHD patients have to work harder than normal muscles, but fatigue may also have additional causes. Some FSHD patients have been found to have respiratory impairment, including sleep apnea and lower than normal forced vital capacity. The causes have not yet been definitively proven, but many doctors believe that FSHD may be an important factor. If you feel fatigue, discuss it with your doctor. If while sleeping you breathe in a labored manner or momentarily stop breathing, this may indicate sleep apnea or other respiratory impairment; again, discuss it with your doctor. Because some doctors, even experienced neurologists, don’t associate FSHD with respiratory problems, your doctor may be reluctant to order respiratory tests; be persistent if you feel fatigue or sleep problems. The doctor may order breathing tests including forced vital capacity and nocturnal oxymetry tests, and blood tests such as a blood gas test. These are non-invasive tests that generally don’t require a hospital stay. A sleep study is a more complex test that may require an overnight hospital stay. The doctor may prescribe CPAP, BiPAP, or other mechanical ventilation at night to help breathing, increase oxygen, and improve sleep. CPAP, BiPAP, and similar mechanical ventilation devices are small machines that blow air into a patient’s nose, which assists the patient in exhaling. The air is delivered by a hose running from the machine to a mask or similar apparatus around the patient’s nose. The doctor may order the tests to be repeated periodically to ensure that the settings on the machine are appropriate. A respiratory therapist (RT) is a health professional trained in respiratory health and problems. An RT should be part of the team that monitors respiratory health. The doctor and RT may recommend stacked breathing exercises. These exercises involve a facemask attached to a football-shaped plastic bladder. A helper holds the face mask around the mouth of the person doing the exercise. The person inhales rapidly several times in succession without exhaling, while the helper squeezes the bladder to push air into the person’s lungs. This exercises the chest muscles and increases oxygen intake. These exercises don’t require much time, and a family member can help an FSHD patient do them. FSHD patients who can’t walk may be at risk of developing blood clots on long airplane flights. On the advice of their doctors, some people take an anti-blood clotting prescription medication before flights to reduce the risk of clotting. See also the sections on Respiratory Therapists and Pulmonologists.
BreatheNVS is an excellent web resource for management of respiratory issues through noninvasive support. The site is being developed by Dr. John Bach, a professor of Physical Medicine & Rehabilitation, professor of Neurosciences, the director of the New Jersey Medical School Muscular Dystrophy Association Clinic, and medical director of the Center for Ventilator Management Alternatives.
Links to Recent Articles About Respiratory Problems in FSHD
- 2010 FSH Society International Patient and Researcher Network Meeting, July 30–August 1, 2010. Presentation slides for talk titled: Breathing and Respiratory Health for People with FSHD, by Joshua O. Benditt, MD, Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle. Click here to read Abstract.
- Della Marca G, Frusciante R, Vollono C, Dittoni S, Galluzzi G, Buccarella C, Modoni A, Mazza S, Tonali PA, Ricci E. Sleep quality in Facioscapulohumeral muscular dystrophy. J Neurol Sci. 2007 Dec 15;263(1-2):49-53. Epub 2007 Jun 26. Click here to read Abstract.
- Simonds AK. Respiratory complications of the muscular dystrophies. Semin Respir Crit Care Med. 2002 Jun;23(3):231-8. Click here to read Abstract.
- Carter GT, Bird TD. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2005 Jan 25;64(2):401. Click here to read Abstract.
- Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2004 Jul 13;63(1):176-8. Click here to read Abstract.
- All those who have a neuromuscular disorder, even if their symptoms are very mild.
- Everyone who has, or had, a relative with a neuromuscular disorder.
- Professionals involved with the care of people with NMD around operations or treatment under local anesthetics.
Anesthetics People with neuromuscular disorders must take great care if they are to have a local or general anesthetics. Even someone with very mild, or non-existent symptoms, or someone who has a family history of a disorder, needs to let the anesthetist know well in advance so that tests can be carried out and proper care after the operation can be arranged. Many people are afraid of having an anesthetics, mainly through ignorance, but when we look at the rate of complications and even deaths arising from anesthesia we see that it is, in fact, very safe. This safety is the result of a thorough understanding of the patient’s medical condition with a careful assessment before the operation, marked technical improvements in monitoring facilities during the operation, and the provision of good recovery facilities such as High Dependency Units (HDU) and Intensive Care Units (ICU). Patients with neuromuscular disorders (NMDs) deserve special attention when it comes to anesthesia because many of the agents used (gases and chemicals) have effects on both muscle and nervous tissue. The main areas of concern are how the anesthetics agents will affect the muscle and nervous tissue including the heart, which is, itself, a muscle. A skeletal deformity such as scoliosis, or curvature of the spine, can also affect the way the patient responds to anesthesia so it is important to consider that, too. Anesthetics and the heart An article printed in the Winter, 1995, No. 20 edition of The Search, showed how people with NMDs could sometimes have associated heart disease. This can occur as a cardiomyopathy, when the heart muscle doesn’t work effectively, or as a defect in the way the electrical activity of the heart is transmitted, a conduction defect. The anesthetics vapors—the smelly agents such as ether and halothane that are inhaled—can reduce the effectiveness of the heart’s muscle contractions and also aggravate any conduction defect. The vapors are all slightly different from each other, some having more effect on the heart than others. So it is important that the anesthetist makes a good assessment of the heart’s condition before the operation which would include the level of physical activity that the patient can manage, and an ECG. Occasionally a more extensive assessment is needed. Anesthetics and breathing Doctors need to measure how weak the patient’s muscles are, usually by assessing the amount of physical activity that the patient can perform, and by taking a blood test to measure levels of a muscle enzyme, creatine kinase (CK). Any anesthetics agent that affects the muscles will also affect the muscle we use to breathe. Strong analgesic or sedative agents will affect these muscles indirectly, and muscle relaxants will have a direct effect on them. As breathing (or respiration) may already be difficult for patients with NMDs, these drugs should be used cautiously, and monitoring of breathing after the operation is absolutely essential. As a result, the patient is usually best cared for in a High Dependency Unit or Intensive Care Unit immediately after the operation. The muscles used for swallowing can also be affected which is another reason why good post-operative care is important. Muscle relaxants Muscle relaxant drugs should only be used if essential because they tend to have a more profound and prolonged effect in NMD patients compared to other patients. One type of muscle relaxant, called suxamethonium, should usually be avoided. It causes the release of potassium ions (K+) from the muscle tissue into the blood. In normal patients this is usually of little practical significance. In patients with NMD the muscle may normally leak K+ so that a further increase in the levels of K+ in the blood may cause abnormal heart rhythms. A pre-operative blood test to check K+ levels is therefore important. Local anesthetics A local anesthetic works by preventing the normal electrical activity in the nerve around which the anesthetics agents are placed. For minor procedures, such as stitches for cuts, they are probably the first choice for patients with NMD because they have few, if any, side effects. However for major local anesthetics techniques, e.g. spinal or epidural, careful assessment of the patient is needed and the type of NMD considered well before the operation. Changes in body temperature and pre-operative “starvation” Patients with NMD do not tolerate changes in body temperature or the starvation often associated with anesthesia or surgery as well as normal patients, so steps need to be taken to minimize these problems by keeping the patient warm and well hydrated using drips. Malignant hyperthermia (MH) and Central Core disease Malignant hyperthermia (MH) is an inherited disorder, which causes an unexpected, sometimes fatal, reaction in the patient to certain anesthetic drugs. Because some patients with NMD have sometimes experienced similar problems during anesthesia, there have been claims that patients with NMD may also have MH. However, it is generally accepted that the only neuromuscular condition truly related to MH is Central Core Disease (CCD), although this is not always the case. Patients with CCD should be considered potentially susceptible to MH unless proved otherwise by a special type of muscle biopsy, which screens for MH. To sum up . . .
- Clearly anesthesia for patients with a NMD is not to be undertaken lightly. Such patients should expect the anesthetist to make a careful and thorough assessment of their particular condition and their current state of health.
- They are not suitable to be treated as ‘Day Cases’ because doctors should carry out pre-operative investigations, and enough time and recovery facilities should be available after the operation.
- It is absolutely essential that the person affected by a NMD should inform the anesthetist even if there are only minor symptoms or no symptoms at all. Occasionally a neuromuscular disorder in a person who had no symptoms has come to light only because of an unexpected problem with anesthesia, particularly in young children. The anesthetist should also be warned if there is an inherited NMD in the family.
- If possible, ask for the anesthetist to be forewarned before admission to hospital and consider wearing a Medic Alert bracelet or similar informational device in case of accidents.
- It is always a good idea to make sure hospital staff have copies of “Fact Sheets” about your condition. If you are going to have an anesthetics, you might want to show your anesthetist this article.
* * * * * * * * *
An Overview of Anesthetic Concerns for Persons Diagnosed with FSHD, by Raymond A. Huml, M.S., D.V.M., R.A.C. From the FSH Watch Newsletter winter 2008. Introduction I became part of the FSHD family when my daughter was diagnosed with FSHD at Duke University’s Muscular Dystrophy Association Clinic in 2003. Since that time, I have liaised with the officers of the FSH Society, genetic specialists at Duke University and other academic and medical centers in order to better understand the disease and its progression. While I have come to understand that, as yet, we cannot change FSHD genetics or cure FSHD, I do believe that some potentially life threatening situations for persons with FSHD can be minimized or eliminated. After a recent trip with my daughter, by ambulance, to an emergency room (ER) for a suspected seizure, I have come to the conclusion that every person with FSHD and their caregivers should be prepared to give details about FSHD and key potential anesthetic complications associated with it, while in the ER, the intensive care unit (ICU) or prior to elective surgery. This article will explain and examine several key anesthetic concerns for persons with FSHD and is intended to encourage those with FSHD (or their caregivers) to be proactive in providing information about FSHD to those providing medical care. It is not intended to serve as medical advice. Anesthetic concerns Even within the high-quality medical care system in America, not all medical staff—including nurses, residents, and interns—are familiar with muscular dystrophies and neuromuscular diseases.
- Regarding my recent trip to the ER, it would have been helpful to have a laminated one page description, with websites, available to give to the medical personnel. The FSH Society can also act as a resource in providing information and fact sheets.
The basic anesthetic concern for all persons with neuromuscular diseases, including those with FSHD, is that the respiratory system, due to a weak diaphragm muscle or chronic response to elevated carbon dioxide levels, can be additionally compromised with oral, intravenous or inhaled drugs (or even the inappropriate use of oxygen). For example, muscle relaxants, like valium, can suppress respiratory function by compromising the diaphragm, and opioids (for pain), while not directly affecting the lungs, can have central (i.e., brain) effects that can compromise the respiratory system. Respiratory insufficiency can occur in all persons with FSHD. However, evaluation of the symptoms and signs of respiratory insufficiency during routine clinic visits is probably more important in patients with moderate to severe FSHD. The first pulmonary visit can be used as a baseline tool; subsequent visits can be used to determine if pulmonary function is changing over time.
- After meeting with a pediatric neurologist with my daughter as a follow-up to the ER visit, I discussed my concerns regarding anesthesia, and we agreed it would be prudent to get a baseline pulmonary function exam.
Regular monitoring of respiratory function is important because insufficiency can occur gradually, over a long period of time without clinical signs. Symptomatic respiratory insufficiency can initially be managed with night time non-invasive pressure support like a Bilevel Positive Airway Pressure (BiPAP) machine which helps get more air into the lungs. In severe cases, FSHD patients may require the use of invasive mechanical ventilation. In standard practice, trauma, ER, ICU, surgery and anesthesiology settings, care should be taken not to suppress respiratory drive with narcotics. Oxygen supplementation can be detrimental to patients with hypercarbic (high CO2) respiratory failure and lead to worsening (i.e., higher) carbon dioxide (CO2) levels. Oxygen should generally not be administered unless BiPAP or similar ventilatory support is also being used.
- During the 15-minute ambulance ride to the ER with my daughter, I found it impossible to convince the EMS staff that oxygen supplementation was exacerbating the symptoms—especially since there were no obvious signs of respiratory insufficiency—like increased or labored breathing or blue lips—and normal pulse oximetry readings.
Your physician and pulmonologist can help you periodically monitor CO2 levels in the office or evaluate pulmonary function in the hospital, or even by a nocturnal oxymetry study. The timing for the periodic monitoring of pulmonary function will be determined by the results of the baseline visit, any new clinical signs, you, your pulmonologist and your neurologist may discover. Elective surgery, surgery for dentistry, or surgery that allows some planning time Anyone having surgery should be aware of the risks associated with the surgical procedure and/or complications that may arise during and/or after it. While certain risk factors are increased in people with FSHD who undergo anesthesia, each individual is different and reactions to anesthetics may be different. As with all medical procedures, you should talk to your physician about the specifics of your case and what you should anticipate and hopefully have baseline data available for physician review—like pulmonary function data. The following is a brief description of complications that may occur among people with FSHD who have surgery. Complications from anesthesia While this list is not exhaustive, complications in patients with FSHD who have had anesthesia during surgery can include the following:
- respiratory distress
- rhabdomyolysis (muscle degeneration)
- cardiac complications
- myotonia (decreased ability to relax the muscles)
- generalized muscle spasms (particularly the jaw muscle)
- hyper and hypothermia (abnormally high and low body temperature).
Some of these complications appear to be related to the symptoms, severity and stage of FSHD, while other complications, such as respiratory or heart problems, appear to be related to secondary conditions. For example, while rhabdomyolysis appears to be a complication related to NMD symptoms, breathing problems are most often associated with a respiratory problem that is secondary to the muscle weakness caused by the disease process. There are no definitive ways to completely alleviate all risks; however, there are several precautions, like pre-operative testing, that physicians can take to lessen the likelihood of these complications. Pre-operative testing One way to prevent or alleviate complications from surgery in individuals with FSHD is through pre-operative testing. These tests may or may not be done based upon the information already contained in your medical records (i.e., symptoms and severity, whether or not you are known to have heart or respiratory problems, etc.). If your physician does not have sufficient information, she/he may run a variety of tests (see below for examples of preoperative tests) to determine:
- what types of anesthetics to use (i.e., local vs. regional vs. general)
- what drug combination to use for anesthesia
- what types of pre- and post-operative measures should be taken to lessen the likelihood of complications.
For patients with FSHD who have not had these tests performed earlier, these pre-operative tests are recommended:
- baseline pulmonary function testing
- baseline neurologic testing (clinical or diagnostic like EEG)
- baseline cardiac testing such as an electrocardiogram (ECG).
Identification of a potential problem to medical persons Without a caregiver present or the ability to speak coherently, medical personnel may not know that you have FSHD. FSHD patients should take care with their advanced medical directives and health care proxies to be sure that the “do not resuscitate clause” does not put them at risk. Use of a bracelet, necklace, etc., from MedicAlert (or a similar service) will notify medical personnel to potential problems associated with FSHD. A USB flash memory drive with medical files (in PDF or MS Word formats) is an alternative way to transport medical information in a purse or pocket. On the other hand, use of a bracelet or necklace in adolescents can be problematic because, at this age, it identifies the person afflicted with FSHD to a nontargeted (e.g., non-medical) audience. It may be possible, in lieu of a bracelet, to carry such identification card in the wallet or purse. Conclusions
- Not all medical personnel are well-informed about FSHD or may not know that you have FSHD unless it is communicated to them either verbally or via a MedicAlert-type device.
- Persons with FSHD manifest a wide variety of clinical symptoms of the disease.
- There are some complications of anesthesia that are more prevalent amongst people diagnosed with moderate or severe FSHD.
- You and your caregiver should be an informed participant in any surgical procedure. It is prudent to learn more about the respiratory implications of anesthetics before they become a problem.
- Being aware of the potential complications that may be associated with the use of anesthesia with FSHD and discussing the risks and benefits with your physician before choosing a particular procedure is the best way to prepare for surgery or an emergency room visit and to keep risk at a minimum.
- Review estate planning documents to insure that they are consistent with the medical intervention you wish to receive if you are unable to communicate.
See also Anesthesiologists. References:
- Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of Anaesthesia in Neuromuscular Disorders. Neuromuscul Disord. 2005, Mar;15(3):195-206. Epub 2005 Jan 28. Department of Anaesthesiology, Ulm University, Albert-Einstein-Allee 11, 89069 Ulm, Germany. Click here to read Abstract.
- Halsall and Ellis. Anesthetics, Academic Unit of Anesthesia, St. James University Hospital, Leeds, The United Kingdom, FSH Watch, Spring 1998.
- Respiratory Therapeutics in Neuromuscular Disease, NMDinfo.net, accessed November 15, 2007.
- Personal communication: Perez, D. President and CEO, FSH Society, 2007.
- Personal communication, Abresch, RT. Director of Research, Center for Neuromuscular Disease at UC Davis, Davis, CA, 2007.
- Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G, Tonin P, Mongini T, Palmucci L, Galluzzi G, Tupler RG, Barchitta A. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol. 2006;56(1):1-5. Epub 2006 Jun 27. Click here to read Abstract.
- Galetta F, Franzoni F, Sposito R, Plantinga Y, Femia FR, Galluzzi F, Rocchi A, Santoro G, Siciliano G. Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2005 Jun;15(6):403-8. Epub 2005 Apr 21. Click here to read Abstract.
- Emmrich P, Ogunlade V, Gradistanac T, Daneschnejad S, Koch MC, Schober R. Facioscapulohumeral muscle dystrophy and heart disease [Article in German] Z Kardiol. 2005 May;94(5):348-54. Click here to read Abstract.
- Laforêt P, de Toma C, Eymard B, Becane HM, Jeanpierre M, Fardeau M, Duboc D. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology. 1998 Nov;51(5):1454-6. Click here to read Abstract.